Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes is a research paper published in Neuro-Oncology Advances (2021). On theSindex it has a DataRank of 0. It has been cited 21 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5R01NS104147-02
Selfridges Group Foundation
FWCI
1.14
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals